Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biopharmaceuticals
Array BioPharma Advances p38 / Tie2 Inhibitor, ARRY-614, into Phase 1 Clinical Trial
April 8th, 2008
Array BioPharma Inc. (NASDAQ: ARRY) filed an Investigational New Drug (IND) application for ARRY-614 with the U.S. Food & Drug Administration and has initiated a Phase 1 clinical trial. ARRY-614, a potent, orally active p38 / Tie2 inhibitor, has shown good efficacy and a low side effect profile in preclinical models of human cancer and arthritis. The compound will initially be evaluated in a single and multiple dose escalation study in normal, healthy volunteers for safety, tolerability, exposure and inhibition of mechanism-related biomarkers. "We believe the dual inhibition of p38 and Tie2 may produce additive and/or synergistic effects with other therapies in treating...
Source: Cancer Weekly (2008-04-08)
|
